Ma, Z. , Li, L. and Shi, C. (2025) Schwannoma of the Nasal Septum: A Case Report and Literature Review. Journal of Biosciences and Medicines, 13, 410-419. doi: 10.4236/jbm.2025.1311029 .

Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) ...

"For people living with CRSwNP, every breath can feel like a struggle, and many endure years of recurring symptoms and surgeries without significant relief. The approval of TEZSPIRE represents a ...

About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP [nasal polyps]) CRSwNP is a complex inflammatory disorder characterized by persistent inflammation of the nasal mucosa accompanied by benign ...

Things are beginning to spiral out of control for West Virginia this season, getting outscored over the past two weeks, 89-24. "Disappointing. It's embarrassing how we just failed to execute and ...